Useful for individuals who are experiencing symptoms, but do not have a clear medical history that would help clinicians confirm diagnosis of genetic disorders and act accordingly.
Designed for healthy individuals without symptoms or medical history to provide them with a proactive approach to understanding their genetic risk for certain conditions.
Designed for individuals and families to provide them with a comprehensive and accurate solution for assessing their genetic predisposition to inherited conditions.
Whole Genome Sequencing (WGS)
Unlike other genetic tests that only analyze a small portion of a patient's DNA, Whole Genome Sequencing provides a complete and accurate genetic profile for each patient.
This advanced level of testing allows clinicians to detect the presence or predisposition of genetic diseases with unprecedented precision, providing personalized, reliable diagnoses and treatments for each patient's unique genetic makeup.
But the benefits of WGS don't stop there. It also enables advanced precision medicine, which tailors treatment plans to each patient's specific genetic profile. This leads to better patient outcomes, improved quality of life, and reduced healthcare costs in the long run.
Whole Genome Sequencing is the only technology that can decipher the entire DNA.
Dante's WGS overcomes the shortcomings of Whole Exome and Panel Sequencing.
Partnering with Dante Genomics means
The outsourcing model available through the partnership with Dante Genomics allows greater flexibility in delivering high-quality data to patients, in a cost-effective and simplified logistics mannercost-effectively, without fixed costs, and by outsourcing all logistical implications to reach the individual patient.
Sends the sample kit directly to the patient
Ships the sample to laboratories
Analyzes the sample using NGS technologies
Releases raw data and insightful, actionable reports
Benefits you will get
By using genomics to personalise treatment, hospitals can improve patient outcomes, which can help attract and retain patients. For example, by identifying genetic mutations that make a patient more susceptible to a certain condition, doctors can tailor treatment plans to manage the condition better and improve outcomes.
Genomics can identify patients at risk for certain conditions, allowing for early intervention and potentially reducing costs. For example, by identifying genetic risk factors for heart disease, doctors can develop early intervention plans to prevent or mitigate the disease, potentially reducing costs associated with later-stage treatment.
Improved accuracy in diagnostics
Genomics can be used for diagnostic purposes, which can help to improve accuracy and speed up the diagnostic process, reducing costs and improving patient outcomes. For example, by using genomics to identify the specific genetic mutations associated with a particular condition, doctors can more accurately diagnose and treat the condition, reducing the need for costly and time-consuming diagnostic tests.
By providing an additional product for patients and engaging with them directly to play an essential role in their own personalised medicine, hospitals can partner with their patients and increase revenues with these new products and services in the process.
Efficient and easy implementation
By leveraging a decentralised model, such as the one offered by Dante Genomics, hospitals can easily implement personalised medicine by offering whole genome sequencing without the need for significant upfront investments in technology or infrastructure, unlike other traditional laboratory tests
Leverage the best technology
Dante Genomics offers whole genome sequencing, a one-stop-shop platform for well-being and diagnosis that lasts forever. This is a new concept compared to the old genomic targeted panels that function as confirmatory testing.
Non-invasive sample collection
Dante uses non-invasive collection kits; hospitals can efficiently and easily collect genomic data from patients, making the process of implementing personalised medicine quick and easy.
Tailor-made, end-to-end services
Dante Genomics offers an end-to-end solution that is fully customisable, including white labelling options, so that it can be tailored to your hospital's specific needs. There are no hidden costs, and logistics are included in our service.
Dedicated Onboarding and Customer Success Programs
Gain access to personalised and dedicated onboarding and customer success programs with dedicated training programs to help doctors implement genomics and benefit in the daily practice. Dante Genomics also provides peer-to-peer support with a Clinical Genomic Board to assist in the implementation process and ensure success.
The power of the entire DNA
Receive actionable insights based on the sequencing of the whole genome.
Leverage our proprietary Extensa software platform for genomic interpretation to gather relevant insights.
Genome Manager Platform
Our Genome Manager Platform allows either you or your patients to track genome analysis from sample receipt to end of analysis to results delivery.
After registering on the Genome Manager Platform you can view and download the panels you have purchased or buy additional ones.
We developed more than 130 panels for several needs and conditions, from clinical areas and rare diseases to wellness applications.
Our panels translate genomic raw data information into actionable, clinically relevant insights for clinicians and individuals.
Whole genome sequencing is becoming a top platform in molecular diagnostics, with potential to replace other technologies due to its scalability and decreasing cost.
Industry evolution and needs
- WGS is replacing multiple technologies for comprehensive analysis
- Decreasing cost of whole genome sequencing drives adoption in diagnostics
- Clinicians demand actionable insights from raw whole genome data
- Explosive data growth demands a scalable platform for clinical decision making
- Value shift from hardware to software in molecular dignostics
Krantz et al, 2021
2017-2019 NICUSeq trial
354 critically ill infants
1 country (USA)
2-fold higher diagnostic yield compared to usual care testing.
WGS was associated with significant increase in focused clinical management.
Petrikin et al, 2018
2014-2016 NSIGHT1 trial
1 country (USA)
Median time to diagnosis with WGS was 13 days vs. 107 days with standard clinical testing.
Scocchia et al, 2019
2016 via Illumina program, iHope
1 country (Mexico)
The diagnostic rate of WGS was 68.3% and a change in clinical management was reported in 48.8% of all cases.